WILLIAMSVILLE, N.Y.--(BUSINESS WIRE)--22nd Century Group, Inc. (OTCBB: XXII), a company focused on smoking cessation and tobacco harm reduction products, today announced that its wholly-owned subsidiary, 22nd Century Limited, LLC, enrolled the first patients in its Phase II-B clinical trial for X-22, a prescription smoking cessation aid in development.
